论文部分内容阅读
白细胞介素6(IL-6)作为一种抗肿瘤因子或化疗后血小板刺激因子已开始在临床上应用。初步研究已经显示重组人白细胞介素6(rhIL-6)可引起正色素正细胞性贫血,但至今这种贫血的病理生理学机制尚不清楚。为了阐明其内在机制,选择15例接受rhIL-6作为抗肿瘤免疫治疗的癌症患者进行研究。 病人和方法 15例癌症患者中,7例为转移性肾细胞癌,8例为恶性黑色素瘤;其中男性10例,女性5例,年龄25～62岁,平均49岁。rhIL-6用法为:150μg,
Interleukin 6 (IL-6) has been used clinically as an anti-tumor factor or platelet stimulating factor after chemotherapy. Preliminary studies have shown that recombinant human interleukin 6 (rhIL-6) can cause orthoplasia positive cell anemia, but the pathophysiology of this anemia is unclear. In order to elucidate its intrinsic mechanism, 15 patients who received rhIL-6 as anti-tumor immunotherapy were selected for study. Patients and Methods Of the 15 cancer patients, 7 were metastatic renal cell carcinoma and 8 were malignant melanoma; 10 males and 5 females, aged 25-62 years, mean 49 years old. rhIL-6 usage: 150μg,